Fenwick & West LLP | USA | 19 Jan 2023
Differences in their stage of development, including the relative importance placed on various business objectives (for example, focus on growth and…
Taylor Wessing | United Kingdom | 18 Jan 2023
The Associate of the British Pharmaceutical Industry (ABPI) announced on 16 January that two global pharmaceutical companies, Eli Lilly and AbbVie…
Pearce IP | Australia | 16 Jan 2023
Korea Biomedical Review reported that Dong-A STl has published the results of its global Ph III trials of DMB-3115 (biosimilar ustekinumab). Dong-A…
Gowling WLG | Canada | 16 Jan 2023
Canadian Courts issued many life sciences decisions in 2022. This article summarizes a number of the more notable court decisions, as well as other…
Venable LLP | USA | 12 Jan 2023
BiologicsHQ's "Spotlight On" product dashboards provide, at a glance, an overview of the status of U.S. patent proceedings. The dashboards concerning…
Smart & Biggar | Canada, Global | 12 Jan 2023
2022 was an active year in Canadian patent law. Claim fees were introduced for the first time; changes were made to regulations providing remedies for…
K&L Gates LLP | USA | 6 Jan 2023
On 21 July 2022, the Third Circuit in Perrigo Co. v. AbbVie Inc. affirmed the district court's judgment that the mutual release in the settlement…
Smart & Biggar | Canada | 4 Jan 2023
The Federal Courts released the following patent decisions in 2022, all relating to s. 6(1) actions under the Patented Medicines (Notice of…
Pearce IP | Australia, European Union, USA | 19 Dec 2022
Zhejiang Doer Biologics announced a clinical trial collaboration agreement with Merck to evaluate DR30303 (humanized anti-Claudin18.2 heavy chain…